Economic evaluations of RSV preventive strategies: a systematic review of cost-effectiveness and modeling approaches.

ABSTRACT:

Background

Respiratory syncytial virus (RSV) causes significant morbidity and mortality worldwide, particularly in high-risk groups. Despite the availability of preventive interventions, it is crucial to evaluate the economic benefits of these interventions.

Methods

This systematic review assessed the cost-effectiveness and model structures of RSV prevention strategies, including vaccines and monoclonal antibodies, by analyzing studies published up to March 2025.

Results

A total of 39 studies were included, comprising one cost-benefit analysis (CBA) and 38 cost-effectiveness analyses (CEAs), utilizing six different types of economic models. The incremental cost-effectiveness ratio (ICER) among the older adult population varied from $5,342 to $385,829 per quality-adjus

SUBMITTER: Zhu B 

PROVIDER: S-EPMC12554770 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature